Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Echo Therapeutics fiscal 2010 net loss decreases to $4.1 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the year ended December 31, 2010.

21 Mar 2011

Equipois debuts x-Ar exoskeletal arm support system for manual tasks at Applied Ergonomics Conference

Equipois Inc., designer and manufacturer of the zeroG® mechanical arm technology, debuted today the x-Ar™, the world's first exoskeletal arm support system for manual tasks, at the Applied Ergonomics Conference in Orlando, Florida.

21 Mar 2011

Advanced Cell Technology reduces 2010 debt to less than $1 million

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today 2010 year-end results for the period ended December 31, 2010. The Company utilized $8.8 million in cash for operations during the year, compared to $5.1 million in the year-earlier period.

21 Mar 2011

Medicago launches clinical development of seasonal flu vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the first dose of vaccine has been administered thereby initiating the Company's phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States. The primary safety and immunogenicity results for this trial are expected within three months.

21 Mar 2011

FDA meets ambitious implementation deadlines set forth in tobacco law

Since the passage of the Family Smoking Prevention and Tobacco Control Act in 2009, the U.S. Food and Drug Administration has met the ambitious implementation deadlines set forth in the law, the agency said Wednesday at a congressional briefing hosted by the American Association for Cancer Research.

19 Mar 2011

Researchers develop new system that documents healing process in detail

Knee patients need patience: injuries to these joints take weeks to heal. Fraunhofer researchers have now developed a system that documents the healing process in detail. This motivates patients and at the same time helps doctors to fine-tune the course of treatment.

19 Mar 2011

Protalix prices underwritten public offering of 4,000,000 shares of common stock

Protalix BioTherapeutics, Inc., announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $5.50 per share.

18 Mar 2011

Alnylam to defend against Tekmira complaint

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is reporting the filing of a complaint by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court. The complaint alleges misappropriation and misuse of information, amongst other allegations.

18 Mar 2011

Covidien provides update on its operations in Japan

Covidien, a leading global supplier of healthcare products, today provided an update on its operations in Japan.

18 Mar 2011

Cangene second quarter revenues increase 3% to $40.2 million

Cangene Corporation today reports financial results for the quarter ended January 31, 2011, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

18 Mar 2011

Protalix intends to sell shares of its common stock in underwritten public offering

Protalix BioTherapeutics, Inc. announced today that it intends, subject to market conditions, to offer and sell shares of its common stock in an underwritten public offering.

18 Mar 2011

China Botanic first quarter net sales increase 32.1% to $22.6 million

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced financial results for the three months ended January 31, 2011, and reaffirmed guidance for its full fiscal year ending October 31, 2011.

17 Mar 2011

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.

17 Mar 2011

Sparton announces contract manufacturing award from Talyst

Sparton Corporation, a supplier of complex and reliable electronic and electro-mechanical products, sub-assemblies and related services to the highly regulated Medical, Defense & Security, and Aerospace markets, announces an initial contract manufacturing award from Talyst, Inc. located in Bellevue, WA.

17 Mar 2011

Highmark forces patients with PIDD to switch over to specific IgG therapy

Beginning April 1, Highmark Blue Cross Blue Shield will force their insured patients with primary immunodeficiency diseases and other rare disorders to switch their prescription to a single brand of immunoglobulin, regardless of their current IgG therapy.

17 Mar 2011

FAO head highlights food security concerns, need for more agriculture investment

Rising oil prices and the recent drawdown in global cereal stocks could lead to a supply crisis and raise the risk of food riots in developing countries similar to those that occurred between 2007 and 2008, U.N. Food and Agriculture Organization Director General Jacques Diouf said in an interview with Reuters on Monday.

17 Mar 2011

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.

16 Mar 2011

Genesis Biopharma to establish Adoptive Cell Immunotherapy based therapeutic development program

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.

16 Mar 2011

RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold

RegeneRx Biopharmaceuticals, Inc. announced that it has received a notice from the U.S. Food and Drug Administration (FDA) indicating that, due to non-compliance with FDA's current Good Manufacturing Practice (cGMP) regulations by its contract manufacturer, the Company's Phase 2 clinical trial of RGN-352, its injectable formulation of Thymosin beta 4 for the treatment of acute myocardial infarction (AMI), has been placed on clinical hold.

16 Mar 2011

Millennium, SGEN expand ADC collaboration

Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.

16 Mar 2011